Dr. Libing Xiang 向礼兵
Chief Physician
Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of benign and malignant gynecologic tumors, including complex cases such as ovarian cancer with hepatic hilar metastasis. Expertise in advanced and recurrent ovarian cancer surgery, upper abdominal metastasis resection, and laparoscopic fertility-sparing surgery for early cervical cancer.
Dr. Xiang earned a bachelor's degree from Bethune Medical University and master's and doctoral degrees from Fudan University. With nearly 20 years of experience in general gynecology and gynecologic oncology, Dr. Xiang conducts translational and clinical research. Dr. Xiang has published over 10 SCI papers as first or corresponding author, led three National and Shanghai Natural Science Foundation projects, and received two Shanghai Anti-Cancer Science and Technology Awards, two FUSCC Medical Achievement Awards, and one national invention patent.
Name order: in Chinese the family name comes first (Xiang Libing). Papers usually list the name as Libing Xiang or Xiang L.
Selected publications
27 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Gynecol Cancer, 2026 (first author): Surgical technique of hepato-celiac lymphadenectomy in relapsed ovarian cancer. PubMed 41418628
- BMC Womens Health, 2024 (senior author): Prediction of recurrence-related factors for patients with early-stage cervical cancer following radical hysterectomy and adjuvant radiotherapy. PubMed 38297248
- Int J Gynecol Cancer, 2023 (first author): Splenectomy via the posterolateral approach in ovarian cancer. PubMed 37169393
- Int J Gynecol Cancer, 2023 (first author): Resection of metastatic ovarian cancer in the supragastric lesser sac in 10 steps. PubMed 36253004
- BJOG, 2022 (first author): Who really benefits from intraperitoneal chemotherapy for advanced ovarian cancer? A treatment-free survival analysis of the AICE trial. PubMed 36485070
- Acta Biochim Biophys Sin (Shanghai), 2022 (senior author): Inhibition of the PIN1-NRF2/GPX4 axis imparts sensitivity to cisplatin in cervical cancer cells. PubMed 35983979
- BMC Surg, 2022 (senior author): The surgical outcomes and perioperative complications of bowel resection as part of debulking surgery of advanced ovarian cancer patients. PubMed 35246104
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion